These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38635491)

  • 21. Novel therapies for relapsed/refractory mantle cell lymphoma.
    Arora PC; Portell CA
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].
    Rousseau A; Thieblemont C
    Bull Cancer; 2021 Feb; 108(2):142-144. PubMed ID: 33531153
    [No Abstract]   [Full Text] [Related]  

  • 23. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
    Klener P
    Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
    Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
    N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Directions for Mantle Cell Lymphoma in 2022.
    Kumar A; Eyre TA; Lewis KL; Thompson MC; Cheah CY
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35561299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
    Dreyling M; Tam CS; Wang M; Smith SD; Ladetto M; Huang H; Novotny W; Co M; Romano A; Holmgren E; Huang J; Gouill SL
    Future Oncol; 2021 Jan; 17(3):255-262. PubMed ID: 32985902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
    Yamshon S; Martin P
    Clin Adv Hematol Oncol; 2021 Jun; 19(6):376-382. PubMed ID: 34106911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
    Tawfiq RK; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
    Minson A; Hamad N; Cheah CY; Tam C; Blombery P; Westerman D; Ritchie D; Morgan H; Holzwart N; Lade S; Anderson MA; Khot A; Seymour JF; Robertson M; Caldwell I; Ryland G; Saghebi J; Sabahi Z; Xie J; Koldej R; Dickinson M
    Blood; 2024 Feb; 143(8):673-684. PubMed ID: 37883795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease.
    O'Reilly MA; Sanderson R; Wilson W; Iyengar S; Lambert J; McCulloch R; Eyre TA;
    Br J Haematol; 2022 Oct; 199(1):40-44. PubMed ID: 35894253
    [No Abstract]   [Full Text] [Related]  

  • 32. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acalabrutinib for adults with mantle cell lymphoma.
    Jurczak W; Długosz-Danecka M; Wang M
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):179-187. PubMed ID: 30638402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review.
    Al-Mansour M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e1019-e1031. PubMed ID: 36068158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.
    Wallace D; Reagan PM
    Drugs; 2021 Apr; 81(6):669-684. PubMed ID: 33783717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma.
    Yaniv B; Tanenbaum B; Kazakova V; Patel SA
    Leuk Res; 2024 Jul; 142():107519. PubMed ID: 38761562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.
    Lantermans HC; Ma F; Kuil A; van Kesteren S; Yasinoglu S; Yang G; Buhrlage SJ; Wang J; Gray NS; Kersten MJ; Treon SP; Pals ST; Spaargaren M
    Leukemia; 2024 Jul; 38(7):1570-1580. PubMed ID: 38454120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
    Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
    Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bruton Tyrosine Kinase Inhibitors: Present and Future.
    Burger JA
    Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
    Jain P; Wang ML
    Am J Hematol; 2022 May; 97(5):638-656. PubMed ID: 35266562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.